Last reviewed · How we verify
Intravenous sedation with midazolam
Intravenous sedation with midazolam, marketed by Michigan State University, holds a position in the sedation market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Intravenous sedation with midazolam |
|---|---|
| Also known as | Versed |
| Sponsor | Michigan State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
- Continuous Sedation vs Daily Sedation Interruption in Ventilated Children (NA)
- Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial (NA)
- Comparison of Extubation Delay After Prolonged Sedation (PHASE4)
- Efficacy of Dexmedetomidine Versus Midazolam Sedation on Extubation Time in Mechanically Ventilated Preterm Infants (PHASE3)
- Sodium Oxybate Versus Midazolam for Comfort Sedation (PHASE4)
- Midazolam Alone Versus Midazolam With Ketorolac for Sedation During Flexible Bronchoscopy. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous sedation with midazolam CI brief — competitive landscape report
- Intravenous sedation with midazolam updates RSS · CI watch RSS
- Michigan State University portfolio CI